Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedJul 09, 2026
DataAggregated Company Financials
Companies52
  • 7D-4.5%
  • 3M9.4%
  • 1Y39.3%
  • YTD-1.6%

Over the last 7 days, the Pharma industry has dropped 4.5%, driven by a pullback from Curaleaf Holdings of 10%. Meanwhile, Apotex Health actually outperformed within the industry, gaining 18% in the last week. In the past year, the industry has gained 39%. As for the next few years, earnings are expected to grow by 15% per annum.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 09 Jul 2026CA$13.7bCA$10.7b-CA$1,734,872,151.919.9x-7.9x1.3x
Sat, 06 Jun 2026CA$17.6bCA$12.2b-CA$1,906,842,359.488.4x-9.2x1.4x
Mon, 04 May 2026CA$16.9bCA$11.2b-CA$1,662,033,028.7315.4x-10.2x1.5x
Wed, 01 Apr 2026CA$12.4bCA$11.4b-CA$1,685,071,393.8912.4x-7.4x1.1x
Fri, 27 Feb 2026CA$14.7bCA$11.3b-CA$1,805,492,034.8614x-8.1x1.3x
Sun, 25 Jan 2026CA$16.4bCA$11.2b-CA$1,938,988,736.7116.3x-8.5x1.5x
Tue, 23 Dec 2025CA$17.0bCA$11.2b-CA$1,943,217,544.6216x-8.8x1.5x
Thu, 20 Nov 2025CA$12.6bCA$11.4b-CA$1,926,695,653.7614.7x-6.5x1.1x
Sat, 18 Oct 2025CA$17.4bCA$11.3b-CA$2,041,111,924.7235.7x-8.5x1.5x
Mon, 15 Sep 2025CA$15.3bCA$11.2b-CA$2,034,635,474.5240.3x-7.5x1.4x
Wed, 13 Aug 2025CA$16.5bCA$11.7b-CA$2,533,918,367.1622.7x-6.5x1.4x
Fri, 11 Jul 2025CA$10.8bCA$11.7b-CA$2,538,599,628.3419.6x-4.3x0.9x
Sun, 08 Jun 2025CA$9.8bCA$11.7b-CA$2,523,132,318.4618x-3.9x0.8x
Tue, 06 May 2025CA$10.9bCA$11.9b-CA$2,505,074,376.7120.5x-4.3x0.9x
Thu, 03 Apr 2025CA$10.1bCA$12.3b-CA$2,633,078,636.4919.6x-3.9x0.8x
Sat, 01 Mar 2025CA$11.8bCA$12.3b-CA$2,407,221,071.0722.4x-4.9x1x
Mon, 27 Jan 2025CA$12.1bCA$12.1b-CA$2,410,157,394.2135.6x-5x1x
Wed, 25 Dec 2024CA$12.7bCA$12.1b-CA$2,412,536,434.1224.3x-5.3x1x
Fri, 22 Nov 2024CA$14.5bCA$12.0b-CA$2,668,782,094.7716.8x-5.4x1.2x
Sun, 20 Oct 2024CA$19.2bCA$11.8b-CA$2,708,717,422.1217.4x-7.1x1.6x
Tue, 17 Sep 2024CA$18.1bCA$11.6b-CA$2,702,133,400.8920.9x-6.7x1.6x
Thu, 15 Aug 2024CA$18.9bCA$11.7b-CA$2,767,970,359.4124.4x-6.8x1.6x
Sat, 13 Jul 2024CA$19.9bCA$11.7b-CA$3,178,958,933.7019.1x-6.3x1.7x
Mon, 10 Jun 2024CA$20.5bCA$11.8b-CA$2,756,296,099.6812.8x-7.5x1.7x
Wed, 08 May 2024CA$23.5bCA$11.9b-CA$3,425,364,827.9711.1x-6.9x2x
Fri, 05 Apr 2024CA$25.7bCA$11.9b-CA$3,475,772,945.548.9x-7.4x2.2x
Sun, 03 Mar 2024CA$21.7bCA$12.0b-CA$4,217,595,995.489.4x-5.1x1.8x
Tue, 30 Jan 2024CA$22.3bCA$12.3b-CA$6,740,925,133.0010.3x-3.3x1.8x
Thu, 28 Dec 2023CA$17.8bCA$12.2b-CA$6,702,311,326.009.4x-2.7x1.5x
Sat, 25 Nov 2023CA$18.1bCA$12.4b-CA$6,821,980,374.007x-2.7x1.5x
Mon, 23 Oct 2023CA$17.3bCA$12.4b-CA$7,341,920,600.0012x-2.4x1.4x
Wed, 20 Sep 2023CA$20.7bCA$12.9b-CA$7,872,834,219.0014.2x-2.6x1.6x
Fri, 18 Aug 2023CA$13.7bCA$13.0b-CA$8,067,209,385.0011.5x-1.7x1.1x
Sun, 16 Jul 2023CA$15.9bCA$13.2b-CA$9,719,000,603.0012.4x-1.6x1.2x
Price to Earnings Ratio

-1.6x


Total Market Cap: CA$15.9bTotal Earnings: -CA$9,719,000,603.00Total Revenue: CA$13.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -5.8x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 6.7% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market0.18%
Healthcare-0.098%
Pharma-4.47%
Pharma-4.47%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
APTX Apotex HealthCA$38.1718.2%
+CA$1.3b		n/aPE23.3x
NVRS Noveris Health SciencesCA$1.7034.9%
+CA$25.8m		580.0%PE62.1x
GRIN Grown Rogue InternationalCA$0.6414.3%
+CA$20.0m		25.5%PS3.3x
GUD Knight TherapeuticsCA$10.001.5%
+CA$14.7m		63.9%PE175x
VREO Vireo GrowthCA$14.201.4%
+CA$9.2m		-21.1%PS1.3x

Latest News

APTX
CA$38.17
Apotex Health
7D
18.2%
1Y
n/a
GSD
CA$5.12
Devonian Health Group
7D
-37.1%
1Y
-43.1%
ACB
CA$3.80
Aurora Cannabis
7D
-3.8%
1Y
-39.1%
Narrative Update • Jul 07

ACB: Medical Focus And Rescheduling Tailwinds Will Drive Future Upside Potential

Aurora Cannabis’ updated analyst price target has moved from CA$10.00 to CA$8.00 as analysts factor in lower modeled profit margins, a higher discount rate, and more conservative revenue growth assumptions, despite viewing recent partial cannabis rescheduling efforts as extremely favorable for the sector. What is in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining a plan to exit lower margin Canadian consumer and plant propagation businesses and concentrate resources on global medical cannabis, with a focus on markets such as Germany and Poland.
INNO
CA$3.50
InnoCan Pharma
7D
45.8%
1Y
-74.4%
TSND
CA$0.88
TerrAscend
7D
-8.9%
1Y
86.2%
Narrative Update • Jul 02

TSND: Uplisting Preparations And New Jersey Dispensary Deal Will Support Upside

Analysts have lifted their CA$ price target on TerrAscend, reflecting a revised fair value estimate of CA$1.50. This figure is supported by updated assumptions for revenue growth, profit margins, and future P/E levels.
CL
CA$1.12
Cresco Labs
7D
-4.3%
1Y
36.6%
Narrative Update • Jul 02

CL: Expanded Ohio Dispensary Footprint Will Support Future Upside Potential

Analysts have adjusted their CA$ fair value estimate for Cresco Labs from about CA$2.42 to roughly CA$2.72, reflecting updated views on its revenue outlook, profit margins, discount rate and future P/E assumptions. What’s in the News for Cresco Labs Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, the company’s second Ohio dispensary opening in the past month.
CPH
CA$17.01
Cipher Pharmaceuticals
7D
2.0%
1Y
27.6%
NVRS
CA$1.70
Noveris Health Sciences
7D
34.9%
1Y
580.0%
GRIN
CA$0.64
Grown Rogue International
7D
14.3%
1Y
25.5%
GTII
CA$10.46
Green Thumb Industries
7D
-7.0%
1Y
29.8%
CURA
CA$13.73
Curaleaf Holdings
7D
-10.3%
1Y
239.0%
GUD
CA$10.00
Knight Therapeutics
7D
1.5%
1Y
63.9%
Narrative Update • Jun 25

GUD: Latin American Drug Launches And Renewed Coverage Will Drive Future Repricing

Analysts have lifted their price target on Knight Therapeutics by CA$1, reflecting updated assumptions for slightly higher revenue growth and profit margins, along with a modestly lower future P/E multiple. Analyst Commentary Recent research coverage on Knight Therapeutics points to a more constructive tone, with bullish analysts emphasizing the refreshed price target and renewed attention on the stock.
XLY
CA$0.18
Auxly Cannabis Group
7D
2.9%
1Y
20.0%
ALGO
CA$0.21
Light AI
7D
-23.6%
1Y
-19.2%
HITI
CA$3.14
High Tide
7D
-2.8%
1Y
-2.2%
VREO
CA$14.20
Vireo Growth
7D
1.4%
1Y
-21.1%